Bristlecone Advisors’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $1.92M | Buy |
2,512
+655
| +35% | +$487K | 0.16% | 100 |
|
|
2025
Q2 | $1.45M | Sell |
1,857
-90
| -5% | -$69.9K | 0.12% | 115 |
|
|
2025
Q1 | $1.61M | Sell |
1,947
-124
| -6% | -$103K | 0.13% | 125 |
|
|
2024
Q4 | $1.6M | Sell |
2,071
-161
| -7% | -$133K | 0.12% | 120 |
|
|
2024
Q3 | $1.98M | Buy |
2,232
+165
| +8% | +$148K | 0.16% | 109 |
|
|
2024
Q2 | $1.87M | Buy |
2,067
+10
| +0.5% | +$8K | 0.16% | 107 |
|
|
2024
Q1 | $1.6M | Buy |
2,057
+8
| +0.4% | +$5.69K | 0.14% | 117 |
|
|
2023
Q4 | $1.19M | Buy |
2,049
+60
| +3% | +$35K | 0.12% | 127 |
|
|
2023
Q3 | $1.07M | Hold |
1,989
| – | – | 0.12% | 127 |
|
|
2023
Q2 | $933K | Buy |
1,989
+29
| +1% | +$12.2K | 0.09% | 135 |
|
|
2023
Q1 | $673K | Sell |
1,960
-719
| -27% | -$242K | 0.07% | 152 |
|
|
2022
Q4 | $980K | Sell |
2,679
-30
| -1% | -$10.6K | 0.12% | 129 |
|
|
2022
Q3 | $876K | Buy |
2,709
+1
| +0% | +$317 | 0.11% | 125 |
|
|
2022
Q2 | $878K | Buy |
2,708
+949
| +54% | +$285K | 0.11% | 125 |
|
|
2022
Q1 | $504K | Sell |
1,759
-36
| -2% | -$9.27K | 0.06% | 158 |
|
|
2021
Q4 | $496K | Sell |
1,795
-1,314
| -42% | -$333K | 0.06% | 166 |
|
|
2021
Q3 | $718K | Hold |
3,109
| – | – | 0.09% | 136 |
|
|
2021
Q2 | $714K | Buy |
3,109
+110
| +4% | +$22.1K | 0.1% | 129 |
|
|
2021
Q1 | $560K | Sell |
2,999
-184
| -6% | -$36K | 0.08% | 135 |
|
|
2020
Q4 | $537K | Buy |
3,183
+13
| +0.4% | +$1.94K | 0.09% | 134 |
|
|
2020
Q3 | $469K | Buy |
3,170
+44
| +1% | +$6.81K | 0.09% | 130 |
|
|
2020
Q2 | $513K | Sell |
3,126
-183
| -6% | -$28.1K | 0.1% | 121 |
|
|
2020
Q1 | $459K | Sell |
3,309
-1,989
| -38% | -$273K | 0.11% | 117 |
|
|
2019
Q4 | $696K | Buy |
5,298
+2,268
| +75% | +$263K | 0.14% | 115 |
|
|
2019
Q3 | $339K | Sell |
3,030
-2,278
| -43% | -$254K | 0.08% | 126 |
|
|
2019
Q2 | $588K | Buy |
+5,308
| New | +$625K | 0.14% | 111 |
|
|
2019
Q1 | – | Sell |
-4,280
| Closed | -$495K | – | 116 |
|
|
2018
Q4 | $495K | Sell |
4,280
-49
| -1% | -$5.47K | 0.15% | 104 |
|
|
2018
Q3 | $465K | Buy |
+4,329
| New | +$433K | 0.12% | 111 |
|
|
2018
Q1 | – | Sell |
-4,749
| Closed | -$401K | – | 140 |
|
|
2017
Q4 | $401K | Sell |
4,749
-1
| -0% | -$85 | 0.13% | 115 |
|
|
2017
Q3 | $406K | Sell |
4,750
-100
| -2% | -$8.2K | 0.13% | 108 |
|
|
2017
Q2 | $399K | Hold |
4,850
| – | – | 0.14% | 113 |
|
|
2017
Q1 | $408K | Sell |
4,850
-166
| -3% | -$13.3K | 0.14% | 110 |
|
|
2016
Q4 | $369K | Sell |
5,016
-34
| -0.7% | -$2.53K | 0.13% | 116 |
|
|
2016
Q3 | $405K | Buy |
5,050
+150
| +3% | +$12K | 0.15% | 118 |
|
|
2016
Q2 | $386K | Sell |
4,900
-2,725
| -36% | -$205K | 0.14% | 111 |
|
|
2016
Q1 | $549K | Sell |
7,625
-660
| -8% | -$49.9K | 0.22% | 102 |
|
|
2015
Q4 | $698K | Buy |
+8,285
| New | +$688K | 0.3% | 92 |
|
Other funds holding LLY
Bristlecone Advisors's LLY Position: Q3 2025 in Review
Bristlecone Advisors increased its Eli Lilly (LLY) stake by 35% in Q3 2025, buying an estimated $487K and bringing the position to 2,512 shares worth $1.92M. The position accounts for 0.16% of the portfolio, ranked #100.
Bristlecone Advisors first reported a position in LLY in Q4 2015 and has held it in 37 quarters since. The position peaked at $1.98M in Q3 2024. 3,897 funds tracked by Wall St. Rank hold LLY as of Q3 2025.
- Bristlecone Advisors held 2,512 shares of Eli Lilly worth $1.92M as of Q3 2025.
- Bristlecone Advisors bought 655 Eli Lilly shares in Q3 2025, an estimated $487K.
- Eli Lilly made up 0.16% of Bristlecone Advisors's portfolio in Q3 2025, its #100 holding.
- Bristlecone Advisors first reported a position in Eli Lilly in Q4 2015 and has held it in 37 quarters since.
- Bristlecone Advisors's Eli Lilly position peaked at $1.98M in Q3 2024.
- 3,897 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2025.
Based on Bristlecone Advisors's 13F filing for Q3 2025, filed 24 Oct 2025.